02/09/2015 06:36:05 Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
09/01/20158:50AMDJNBristol-Myers Myeloma Drug Accepted for FDA Review
Bristol-Myers Squibb Co.'s Empliciti drug, used to treat multiple myeloma, has been accepted by the U.S. Food and Drug Administration for priority review. Empliciti, also known by the chemical name elotuzumab, is specifically used for multiple myeloma in patients who already have received one or more therapies. It... More...>>
09/01/20158:39AMDJNBristol-Myers Myeloma Drug Accepted for Priority Review
By Angela Chen Bristol-Myers Squibb Co.'s Empliciti drug, used to treat multiple myeloma, has been accepted by the U.S. Food and Drug Administration for priority review. Empliciti, also known by the chemical name elotuzumab, is specifically used for multiple myeloma in patients who already have received one or more... More...>>
09/01/20157:30AMBWU.S. Food & Drug Administration Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for ...
This acceptance for review marks the first in the U.S. for a SLAMF7-directed immunostimulatory antibody Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie (NYSE:ABBV) today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for Empliciti (elotuzumab... More...>>
08/31/20159:40AMDJNBristol-Myers Granted Right to Buy Promedior
Bristol-Myers Squibb Co. said Monday that it has been granted the exclusive right to buy privately held Promedior Inc. and its experimental fibrosis treatment for up to $1.25 billion. Under the terms of the agreement, Bristol-Myers will pay $150 million in cash up front for the right to buy Promedior. Bristol-Myers can... More...>>
08/31/20159:32AMDJNBristol-Myers Granted Right to Buy Promedior for up to $1.25 Billion
By Chelsey Dulaney Bristol-Myers Squibb Co. said Monday that it has been granted the exclusive right to buy privately held Promedior Inc. and its experimental fibrosis treatment for up to $1.25 billion. Under the terms of the agreement, Bristol-Myers will pay $150 million in cash up front for the right to buy Promedior... More...>>
08/31/20158:30AMBWBristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior, Inc. & its Novel PRM-151 in Development...
Bristol-Myers Squibb Company (NYSE:BMY) and Promedior, Inc. announced the companies have entered into an agreement that grants Bristol-Myers Squibb an exclusive right to acquire Promedior and gain worldwide rights to its lead asset PRM-151, a recombinant form of human pentraxin-2 protein in Phase 2 development for the... More...>>
08/30/20157:00PMBWBristol-Myers Squibb & QIMR Berghofer Medical Research Institute Announce Worldwide Collaboration to Discover Novel Immuno-On...
Bristol-Myers Squibb Company (NYSE:BMY) and QIMR Berghofer Medical Research Institute have signed a research collaboration and license agreement to discover novel therapeutic antibodies against an undisclosed immuno-oncology (I-O) target. “Bristol-Myers Squibb continues to invest in strategic partnerships that accelerate... More...>>
08/27/20154:45AMDJNAllied-Bristol Life Sciences Licenses Technology and Molecules from Yale
LONDON--Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise jointly owned between Allied Minds (ALM.LN) and Bristol-Myers Squibb Company (BMY), on Thursday announced that it has entered into a worldwide licensing agreement with Yale University for a platform technology and associated lead molecules that will... More...>>
08/27/20152:00AMBWAllied-Bristol Life Sciences Licenses Platform Technology and Lead Molecules from Yale University
Allied-Bristol Life Sciences (ABLS) has licensed a proprietary platform technology from Yale University, developed in the laboratory of Dr. David Spiegel. The proprietary platform, and associated lead molecules known as Antibody-Recruiting molecules (ARMs), provide a novel approach for the treatment of cancer. Allied-Bristol... More...>>
08/24/20158:15AMBWBristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015
Twenty-two abstracts to be presented, including new analyses from ARISTOTLE and real-world data analyses evaluating the risk of major bleeding, bleeding-related hospital readmissions, hospitalization rates and healthcare costs among patients with nonvalulvar atrial fibrillation (NVAF) receiving novel oral anticoagulant... More...>>
08/20/20155:59AMPRNCAApprobation de DAKLINZA(MC) (daclatasvir) par Santé Canada pour le traitement de l'infection chronique par le virus de l'hé...
Approbation de DAKLINZA(MC) (daclatasvir) par Santé Canada pour le traitement de l'infection chronique par le virus de l'hépatite C de différents génotypes, y compris le génotype 3 Canada NewsWire MONTRÉAL, le 20 août 2015 DAKLINZAMC en association avec le sofosbuvir est le premier... More...>>
08/20/20155:59AMPRNCAHealth Canada approves DAKLINZA™ (daclatasvir) for the treatment of chronic Hepatitis C infection across multiple genotypes...
Health Canada approves DAKLINZA™ (daclatasvir) for the treatment of chronic Hepatitis C infection across multiple genotypes including genotype 3 Canada NewsWire MONTREAL, Aug. 20, 2015 DAKLINZATM in combination with sofosbuvir is the first 12-week, all-oral therapy that offers SVR12 for the vast majority of non-cirrhotic... More...>>
08/13/20158:00AMBWFDA Approves U.S. Product Labeling Update for Sprycel® (dasatinib) to Include Five-Year First-Line & Seven-Year Second-Line ...
Seven-year study matches the longest duration of follow-up for any CML treatment, including imatinib, based on approved prescribing information Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka America Pharmaceutical, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Sprycel® (dasatinib... More...>>
08/12/20157:40PMDJNFDA Decision on Bristol-Myers Squibb Drug Opdiv Is Pushed Back
The Food and Drug Administration pushed back the decision date on an expanded use of Bristol-Myers Squibb Co.'s cancer drug Opdivo to Nov. 27, Bristol-Myers said Wednesday. Bristol-Myers, which initially said a decision was expected by Aug. 27, said it had submitted additional clinical-trial data, which amounts to a "Major... More...>>
08/12/20157:35PMDJNCorrection to Bristol-Myers Squibb Article
The name of Bristol-Myers Squibb Co.'s cancer drug is Opdivo. "FDA Pushes Back Decision on Expanded Use of Bristol-Myers Squibb Drug Opdivo, " at 5:06 p.m. EDT, incorrectly stated the name of the drug in the headline. (Aug. 12, 2015) Subscribe to WSJ: http://online.wsj.com?mod=djnwires More...>>
08/12/20155:36PMDJNFDA Pushes Back Decision on Expanded Use of Bristol-Myers Squibb Drug Opdiv
By Maria Armental The Food and Drug Administration pushed back the decision date on an expanded use of Bristol-Myers Squibb Co.'s cancer drug Opdivo to Nov. 27, Bristol-Myers said Wednesday. Bristol-Myers, which initially said a decision was expected by Aug. 27, said it had submitted additional clinical-trial data, which... More...>>
08/12/20154:15PMBWU.S. Food & Drug Administration Extends Action Date for Supplemental Biologics License Application for Opdivo (nivolumab) in ...
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental Biologics License Application (sBLA) for Opdivo for the treatment of patients with previously untreated advanced melanoma. The company has taken the opportunity to submit... More...>>
08/04/20158:00AMBWBristol-Myers Squibb & The Leukemia & Lymphoma Society Announce Charitable Donation to Support Critical Routine Testing & Awa...
Bristol-Myers Squibb Company (NYSE:BMY) today announced a charitable donation to The Leukemia & Lymphoma Society (LLS). The donation will provide financial assistance for chronic myeloid leukemia (CML) patients who need help paying for Polymerase Chain Reaction (PCR) testing, an important tool used in the diagnosis... More...>>
08/03/20159:00AMBWBristol-Myers Squibb Establishes Collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) Program in the U.S.
Company enters into a collaboration agreement with Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute as part of the I-O RPM program I-O RPM program to focus on patients with high risk, poor prognostic cancers Bristol-Myers Squibb Company... More...>>
07/29/20157:00PMBWKyowa Hakko Kirin & Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab & Opdivo (niv...
Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151,“Kyowa Hakko Kirin”) and Bristol-Myers Squibb Company (NYSE:BMY, “Bristol-Myers Squibb”) today announced that the companies have entered into a clinical trial collaboration agreement to conduct a Phase 1/2 combination study with mogamulizumab, an anti-CCR4 antibody and Opdivo... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse bmy150902 06:36